SEC Form 4 · accession 0001144204-16-080441
Tonix Pharmaceuticals Holding Corp. · TNXP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Seth Lederman
Officer — Chief Executive Officer · Director
Period of report
Feb 9, 2016
Accepted (ET)
Feb 10, 2016 · 5:42 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001430306
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF2,F1 | $5.03 | Feb 9, 2016 | A | 110,000 | A | — | Feb 9, 2026 | Common Stock | 110,000 | 110,000 | D |
| Stock OptionF2,F3 | $5.03 | Feb 9, 2016 | A | 110,000 | A | — | Feb 9, 2026 | Common Stock | 110,000 | 110,000 | D |
Explanation of responses
- F1The option vests 1/3rd on the first anniversary of issuance and 1/36th each month thereafter for 24 months.
- F2The option was granted pursuant to the Issuer's 2014 Stock Incentive Plan.
- F3The option vests 1/3rd upon the date(s) that certain stock price goals are achieved. The stock price goals are such date(s) when the Issuer's common stock has an average closing sales price equal to or exceeding each of $6.00, $7.00 and $8.00 per share for 20 consecutive trading days, subject to a one year minimum service period prior to vesting.